.AN2 Rehabs is rethinking its service in reaction to uninspired midphase data, vowing to give up half its employees and quit a stage 3 study
Read moreALX’s fizzling CD47 action fee delivers inventory spiraling down
.ALX Oncology’s phase 2 stomach cancer cells reaction cost has actually compromised. After seeing its CD47 blocker simply beat control over the 1st half of
Read moreAC Immune views ‘site’ prospective in Alzheimer’s medication records
.After greater than 20 years of work on neurodegenerative diseases, Swiss biotech air conditioning Immune system cases it can possess a video game changer on
Read more